Glioma Clinical Trials

Find Glioma Clinical Trials Near You

Use of CEST (Chemical Exchange Saturation Transfer) Imaging in PET/MRI

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Standard Magnetic Resonance Imaging (MRI) is based on the excitation of hydrogen nuclei that are presents in water molecules, which abundance in human body allows for obtention of superior contrast. However, assessing the presence of other molecules than water in tissues is also of great clinical interest to probe metabolites related to physiological body function and pathological conditions. Chemical exchange saturation transfer (CEST) allow to overcome some limitations of proton magnetic resonance spectroscopy (1H-MRS) by exploiting chemical properties of the targeted molecule through a continuous process of re-saturation and exchange, and thus detecting it with increased sensitivity, from two orders of magnitude. Moreover, CEST technique is based on imaging sequences and can therefore benefit from well-known fast acquisition strategies, as well as improved spatial resolution.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

⁃ Patients admitted to the Nuclear Medicine and Molecular Imaging department of ICANS (Institut de cancérologie strasbourg Europe) for a PET/MRI exam dedicated to:

• Preoperative evaluation of a cerebral expansion lesion

• Evaluation of glioma recurrences

• Evaluation of brain metastases

• Evaluation of recurrence of metastases

Locations
Other Locations
France
France Institut de cancérologie Strasbourg Europe
RECRUITING
Strasbourg
Contact Information
Primary
Manon VOEGELIN
promotion-rc@icans.eu
(0)368339523
Backup
Claire VIT
promotion-rc@icans.eu
(0)368339523
Time Frame
Start Date: 2022-12-28
Estimated Completion Date: 2036-12-28
Participants
Target number of participants: 800
Treatments
Other: Patients with glioma or brain metastases
Related Therapeutic Areas
Sponsors
Leads: Centre Paul Strauss

This content was sourced from clinicaltrials.gov